Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome

PURPOSE: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. PATIE...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Manag Res
Main Authors: Metz, David C, Liu, Eric, Joish, Vijay N, Huynh, Lynn, Totev, Todor I, Duh, Mei Sheng, Seth, Kiernan, Giacalone, Susan, Lapuerta, Pablo, Morse, Michael A
Format: Artigo
Jezik:Inglês
Izdano: Dove 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7548219/
https://ncbi.nlm.nih.gov/pubmed/33116830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S276519
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki